Search results
Results from the WOW.Com Content Network
In 1996, Quintiles buys Innovex Ltd. and BRI International Inc., becoming the world's largest CRO. In 1997, Quintiles goes public, completing a successful secondary stock offering. In 1998, Quintiles becomes the first company in the industry to break the $1 billion mark, when it reports net revenues of $1.19 billion.
The original name of the company was Intercontinental Marketing Statistics, hence the IMS name. IMS Health's corporate headquarters is located in Danbury, Connecticut, United States. The company's chairman and CEO is Ari Bousbib. In 1998, the parent company, Cognizant Corporation, split into two companies: IMS Health and Nielsen Media Research.
Quintiles to Acquire Novella Clinical Acquisition bolsters Quintiles' small biopharma, oncology and medical device capabilities RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- To stay ahead of the ...
Quintiles Completes Acquisition of Novella Clinical RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Quintiles today announced that it has completed the previously announced acquisition of Novella ...
Quintiles Celebrates IPO on the New York Stock Exchange NEW YORK--(BUSINESS WIRE)-- Research Triangle Park, N.C.-based Quintiles, a leading global provider of biopharmaceutical development and ...
Quintiles Named Preferred Provider in Phase I Market Report RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Quintiles is the preferred Phase I service provider and most frequently cited as the ...
In 1994, he took Quintiles public through an IPO. [6] Quintiles is the "largest global provider of clinical trials and commercial marketing services to the pharmaceutical and biotechnology industry". [5] In December 2015, Gillings retired as executive chairman of Quintiles, but remains a director. [6]
Need help? Call us! 800-290-4726 Login / Join. Mail